ArticleProbiotics and antimicrobial proteins2026
Selenium-Enriched Akkermansia muciniphila: A Novel Probiotic Bacterium for Se Supplementation.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Selenium: From Redox Signaling to Interactions with the Gut Microbiome.Biological trace element research · 2026Review
- Biogenic Selenium Nanoparticles from Food-GradeFoods (Basel, Switzerland) · 2026Article
- Bioactivity assessment of selenium nanoparticles biosynthesized by Akkermansia muciniphila.Archives of microbiology · 2026Article
- Gut microbiota: a new perspective for bioavailability of selenium and human health.NPJ science of food · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Selenium (Se)-enriched probiotics have gained widespread application in the fields of food, nutraceuticals, and biomedicine due to their capacity to deliver organic Se with high nutritional value to their hosts. Here, the inorganic Se bioconcentration was employed to generate Se-enriched Akkermansia muciniphila (Se-AM), and we investigated its Se distribution, selenoprotein and selenoamino acid species, essential elements, and amino acid contents. Furthermore, the major probiotic properties of Se-AM were evaluated. The results showed that the Se-AM exhibited remarkable survival and Se enrichment levels. The organic Se content in Se-AM accounted for approximately 81.9%, predominantly composed of protein bound Se (44.3%), followed by nucleic acid bound Se (17.8%) and polysaccharide bound Se (17.4%). The Se element in Se-AM exhibits a preference for binding to proteins with medium molecular weight, predominantly forming selenoamino acids containing SeCys2 and SeMet. Moreover, the content of both individual and total amino acids is higher in Se-AM compared to AM. Furthermore, Se-AM demonstrates robust acid resistance and antioxidant activity along with enhanced adhesion to Caco-2 and HT-29 cells. It also possesses immune-stimulating properties by activating the TLR4/NF-κB signaling pathway in Raw 264.7 cells, leading to increased cytokine release. Transcriptomic analysis reveals elevated expression levels of key genes associated with potent antioxidants, strong cellular adhesion capabilities, and effective cancer cell eradication within Se-AM when compared to AM. Our findings indicated that the Se-AM holds promising potential as a novel probiotic formulation supplemented with Se for both its Se-enhancing properties and probiotic functionality.
Indexed as
Identifiers
40802225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.